FDA Drug Regulator Accused of Targeting Former Business Associate's Pharmaceutical Company
By
duxup
Toasted to a respectable shade. No regrets, no crumbs left.
Summary
The article discusses a scandal at the FDA involving a top drug regulator who allegedly used his position to target a former business associate's company. The regulator posted critical comments on LinkedIn about Aurinia Pharmaceuticals' FDA-approved lupus nephritis drug voclosporin, claiming it lacked proven clinical benefit and proper trials. This caused Aurinia's stock to drop 20% and lose $350 million in market value within hours. The company has filed a lawsuit in response to what it considers an abuse of regulatory power.
Key quotes
· 4 pulledIn a startling post on his LinkedIn account, Tidmarsh claimed that the FDA-approved drug had not been shown to provide 'hard' clinical benefit and that the drugmaker had not performed necessary trials.
Aurinia claims its share price fell 20 percent in a matter of hours, dropping $350 million in market value.
Such a post from the FDA's top drugmaker turned heads.
FDA regulator accused of using position to exact revenge on old business associate.
You might also wanna read
Drugmakers Plan Price Increases on 350+ Medications Despite Government Pressure
Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including COVID, RSV, and shingles vaccines, as well as ca
reuters.com·5mo ago
Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development
The article reveals previously untold history about early GLP-1 drug development in the late 1980s and early 1990s. The author was part of w
statnews.com·5mo ago
Prescription Drug Miebo Costs $800 in U.S. vs. $20 Over-the-Counter in Europe
The article reveals stark differences in drug pricing and accessibility between the U.S. and Europe, using Miebo (EvoTears) as a case study.
statnews.com·5mo ago
Moderna's Post-Pandemic Crisis: From Vaccine Success to Corporate Challenges
The article examines Moderna's current crisis despite its success with the COVID-19 vaccine. After achieving a 95% effective vaccine and mas
statnews.com·7mo ago
Amgen's PCSK9 Patent Battle: Legal Loss but Commercial Victory
This article examines Amgen's legal battle over PCSK9 cholesterol drugs, specifically their patent dispute with Sanofi and Regeneron. Amgen
alexkesin.com·8mo ago
Private Equity Acquisition of Disability Services Raises Regulatory Concerns and Patient Safety Issues
Private equity firms have rapidly acquired over 1,000 disability and elder care service providers in recent years, raising serious concerns
governing.com·9mo ago